SG11201604594SA - Combination therapy with an anti-ang2 antibody and a cd40 agonist - Google Patents
Combination therapy with an anti-ang2 antibody and a cd40 agonistInfo
- Publication number
- SG11201604594SA SG11201604594SA SG11201604594SA SG11201604594SA SG11201604594SA SG 11201604594S A SG11201604594S A SG 11201604594SA SG 11201604594S A SG11201604594S A SG 11201604594SA SG 11201604594S A SG11201604594S A SG 11201604594SA SG 11201604594S A SG11201604594S A SG 11201604594SA
- Authority
- SG
- Singapore
- Prior art keywords
- agonist
- combination therapy
- ang2 antibody
- ang2
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198753 | 2013-12-20 | ||
| EP14158331 | 2014-03-07 | ||
| PCT/EP2014/078233 WO2015091655A1 (en) | 2013-12-20 | 2014-12-17 | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201604594SA true SG11201604594SA (en) | 2016-07-28 |
Family
ID=52278610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604594SA SG11201604594SA (en) | 2013-12-20 | 2014-12-17 | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150232548A1 (en) |
| EP (1) | EP3082857B1 (en) |
| JP (1) | JP6345787B2 (en) |
| KR (1) | KR20160085888A (en) |
| CN (1) | CN105611944A (en) |
| AU (1) | AU2014368695A1 (en) |
| BR (1) | BR112016007112A2 (en) |
| CA (1) | CA2923591A1 (en) |
| CL (1) | CL2016001586A1 (en) |
| CR (1) | CR20160199A (en) |
| EA (1) | EA201600474A1 (en) |
| HK (1) | HK1221409A1 (en) |
| IL (1) | IL244454A0 (en) |
| MX (1) | MX2016008099A (en) |
| PE (1) | PE20160753A1 (en) |
| PH (1) | PH12016500482A1 (en) |
| SG (1) | SG11201604594SA (en) |
| TW (1) | TWI559931B (en) |
| WO (1) | WO2015091655A1 (en) |
| ZA (1) | ZA201601895B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| SG11201701070WA (en) | 2014-08-12 | 2017-03-30 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| KR20170082594A (en) * | 2014-11-10 | 2017-07-14 | 에프. 호프만-라 로슈 아게 | Anti-ang2 antibodies and methods of use |
| BR112017009817A2 (en) | 2014-11-10 | 2018-02-14 | Hoffmann La Roche | anti-il-1beta antibodies and methods of use |
| CN107074941A (en) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Bispecific antibody and for ophthalmologic method |
| BR112017027549A2 (en) | 2015-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | cd40 antibody |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| JP2019521988A (en) * | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | EZH2 inhibitor for treating cancer |
| JP7391845B2 (en) | 2017-12-01 | 2023-12-05 | シージェン インコーポレイテッド | CD47 antibodies and their use to treat cancer |
| US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
| AU2019227997A1 (en) | 2018-03-02 | 2020-09-24 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CA3131250A1 (en) * | 2019-02-25 | 2020-09-03 | Pharmabcine Inc. | Anti-ang2 antibody and use thereof |
| MA55805A (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | METHODS OF MODULATING IMMUNE ACTIVITY |
| TW202115112A (en) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | Anti-angpt2 antibodies |
| CN112168960A (en) * | 2019-07-03 | 2021-01-05 | 义慧科技(深圳)有限公司 | Use of anti-VEGF antibody and anti-ANG2 antibody for the preparation of a medicament for the treatment of tumors with Ras mutations |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| TW202241935A (en) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | Chimeric antigen receptor system with adaptable receptor specificity |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| TWI426920B (en) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
| AR090263A1 (en) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
-
2014
- 2014-12-17 PE PE2016000675A patent/PE20160753A1/en unknown
- 2014-12-17 AU AU2014368695A patent/AU2014368695A1/en not_active Abandoned
- 2014-12-17 EP EP14821592.4A patent/EP3082857B1/en not_active Not-in-force
- 2014-12-17 SG SG11201604594SA patent/SG11201604594SA/en unknown
- 2014-12-17 CN CN201480056156.XA patent/CN105611944A/en active Pending
- 2014-12-17 JP JP2016541193A patent/JP6345787B2/en not_active Expired - Fee Related
- 2014-12-17 BR BR112016007112A patent/BR112016007112A2/en active Search and Examination
- 2014-12-17 CA CA2923591A patent/CA2923591A1/en not_active Abandoned
- 2014-12-17 KR KR1020167016096A patent/KR20160085888A/en not_active Application Discontinuation
- 2014-12-17 WO PCT/EP2014/078233 patent/WO2015091655A1/en active Application Filing
- 2014-12-17 EA EA201600474A patent/EA201600474A1/en unknown
- 2014-12-17 MX MX2016008099A patent/MX2016008099A/en unknown
- 2014-12-18 US US14/575,121 patent/US20150232548A1/en not_active Abandoned
- 2014-12-19 TW TW103144626A patent/TWI559931B/en not_active IP Right Cessation
-
2016
- 2016-03-06 IL IL244454A patent/IL244454A0/en unknown
- 2016-03-11 PH PH12016500482A patent/PH12016500482A1/en unknown
- 2016-03-17 ZA ZA2016/01895A patent/ZA201601895B/en unknown
- 2016-04-23 CR CR20160199A patent/CR20160199A/en unknown
- 2016-06-17 CL CL2016001586A patent/CL2016001586A1/en unknown
- 2016-08-11 HK HK16109582.7A patent/HK1221409A1/en unknown
-
2017
- 2017-10-06 US US15/726,873 patent/US20180134780A1/en not_active Abandoned
-
2020
- 2020-02-28 US US16/804,174 patent/US20200199215A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3082857B1 (en) | 2018-07-25 |
| US20180134780A1 (en) | 2018-05-17 |
| US20200199215A1 (en) | 2020-06-25 |
| IL244454A0 (en) | 2016-04-21 |
| CA2923591A1 (en) | 2015-06-25 |
| PE20160753A1 (en) | 2016-08-01 |
| ZA201601895B (en) | 2018-11-28 |
| EA201600474A1 (en) | 2016-11-30 |
| CR20160199A (en) | 2016-06-17 |
| BR112016007112A2 (en) | 2017-09-19 |
| CL2016001586A1 (en) | 2017-05-12 |
| JP2017504600A (en) | 2017-02-09 |
| US20150232548A1 (en) | 2015-08-20 |
| PH12016500482A1 (en) | 2016-05-16 |
| KR20160085888A (en) | 2016-07-18 |
| MX2016008099A (en) | 2016-10-13 |
| WO2015091655A1 (en) | 2015-06-25 |
| EP3082857A1 (en) | 2016-10-26 |
| AU2014368695A1 (en) | 2016-04-14 |
| CN105611944A (en) | 2016-05-25 |
| JP6345787B2 (en) | 2018-06-20 |
| HK1221409A1 (en) | 2017-06-02 |
| TWI559931B (en) | 2016-12-01 |
| TW201526915A (en) | 2015-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201601895B (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
| IL283040A (en) | E-vaping section and e-vaping device | |
| ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| HK1214972A1 (en) | Supplemental device for use with an injection device | |
| SG10201708409VA (en) | Medicament device | |
| EP2992870A4 (en) | Coinjection device and coinjection method | |
| EP3145565A4 (en) | Combined laryngo-tracheal anesthetic and stylet device | |
| EP2983670A4 (en) | Ibrutinib combination therapy | |
| EP3081627A4 (en) | Well plate and subject selection device provided with well plate | |
| EP2965772A4 (en) | Medicament injection device and storage case therefor | |
| EP2974377A4 (en) | Electromagnetic transducer with specific internal geometry | |
| PL3054856T3 (en) | Device for synchronized injection and aspiration | |
| EP3736003C0 (en) | An injection device | |
| GB201317955D0 (en) | Metering device and parts therefor | |
| HK1224234A1 (en) | Syringe and syringe set | |
| IL242785B (en) | Device for signature adaptation and object provided with device for signature adaptation | |
| EP3010577A4 (en) | Radioactive therapeutic device with fixation | |
| EP3067080A4 (en) | Drug injection device | |
| HUE044705T2 (en) | Furniture fitting with securing device | |
| EP2979200A4 (en) | Query features and questions | |
| EP3088024A4 (en) | Drug injection device | |
| EP2997998A4 (en) | Therapy device for edema and neuropathy | |
| HK1223266A1 (en) | Drug supply unit and drug supply device | |
| EP3027264A4 (en) | Nanochanneled device with electrodes and related methods | |
| EP3067078A4 (en) | Drug injection device |